IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

CPhI: Saltigo shuts US site, abandons plans to build potent API capacity

9:34 AM MDT | October 11, 2012 | Deepti Ramesh in Madrid

Saltigo (Langenfeld, Germany), a Lanxess subsidiary, says it has discontinued production at the company’s Redmond, WA, site and that it has abandoned a previously announced plan to produce potent active pharmaceutical ingredients (API) at that site. “We have decided to focus more on launched products or products in Phase 3 clinical trials and the Redmond site was involved in products required during phases 1 and 2. So we have decided not to continue our activities in the US,” Wolfgang Schmitz, CEO of Saltigo, told CW at the CPhI trade...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa